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Abstract
Objectives: We aimed to evaluate children with type 1 
diabetes (T1D) with early age at onset (EAO) for clinical, 
immune and metabolic features in order to identify age-
related disease phenotypes.
Methods: Comparative study of two groups of T1D chil-
dren: EAO (≤5 years) and later age at onset (LAO; >5 years), 
regarding the presence of other autoimmune (AI) dis-
eases, diabetes ketoacidosis and immunologic profile at 
onset and metabolic data 1 year after diagnosis. Statistical 
analysis was performed with significance set for p < 0.05.
Results: The study included 137 children (EAO = 52, 
mean age 3.6 ± 1.5 [mean ± standard deviation (SD)] and 
LAO = 85, mean age 10.4 ± 2.9). EAO was more associated 
with concomitant AI diseases (p = 0.032). Despite no dif-
ferences in disease onset, EAO presented with lower 
C-peptide levels (p = 0.01) and higher absolute lympho-
cyte number (p < 0.0001), with an inverse correlation 
between these two variables (p = 0.028). Additionally, the 
EAO group had a higher frequency of serum detection of 
three antibodies (Abs) (p = 0.0008), specifically insulin 
Abs (p = 0.0001). One year after diagnosis, EAO had higher 
total daily insulin (TDI) dose (p = 0.008), despite similar 
hemoglobin A1c (HbA1c).
Conclusions: Our data show an association of EAO T1D 
with more AI diseases, higher number of Abs, lower initial 
insulin reservoir and higher insulin requirements 1 year 
after diagnosis. In this group, immune imbalance seems 
more evident and disease progression faster, probably 
reflecting distinct “immune environment” with differ-
ent ages at disease onset. Further studies in the field of 
immunogenetics and immune tolerance are required, to 
improve patient stratification and find novel targets for 
therapeutic intervention.
Keywords: autoantibodies; β-cells; early onset; innate 
immunity; type 1 diabetes.
Introduction
Type 1 diabetes (T1D) is an autoimmune (AI) condition 
characterized by a selective and progressive destruction 
of pancreatic β-cells [1, 2]. Children under 3–5 years of age 
comprise a small proportion of all those with this disorder 
(less than 2% under 3 years of age) [3]. However, current 
evidence suggests a possible trend toward T1D diagnosis 
at a younger age [4]. Importantly, an annual increase of 
5.4% in T1D before the age of 5 years is estimated, and it 
is predicted that this number will double in the coming 
years [5, 6].
Although extensive scientific research has yielded 
important insights into the immune mechanisms involved 
in pancreatic β-cell destruction, little is known about the 
events that trigger the AI process and the factors dictating 
age at onset. In fact, few studies characterize early onset 
T1D, and it is not clear why β-cell destruction is so aggres-
sive in younger children [5, 7].
T1D is characterized by the involvement of cellular 
immunity, genetic susceptibility linked to the human 
leukocyte antigen (HLA) system and about 50 other 
non-HLA loci, as well as the presence of specific circu-
lating autoantibodies [8]. In addition to a strong genetic 
component, environmental factors are clearly involved 
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in the etiology of T1D and may help in explaining its 
growing incidence [9].
Among potential environmental factors, some studies 
support a role for viral infections, particularly enterovi-
ruses, as a trigger for the development of T1D [10].
These triggers can induce the innate immune system 
response and a cascade of events, including the expres-
sion of pro-inflammatory cytokines and chemokines with 
a strong Th1 and Th17 cell response, which allows for cyto-
toxic CD8 T activation [9, 11].
Other studies have directed attention to a population 
of regulatory T cells (Tregs) which play a crucial role in 
the maintenance of homeostasis and self-tolerance of the 
immune system [5, 12, 13].
Furthermore, cell autonomous responses and pos-
sible differences in the early education of the immune 
system should be considered as factors that might affect 
the degree of β-cell damage and the transition from innate 
immunity to adaptive immunity [10].
The appearance of pancreatic autoantibodies in the 
serum is the first sign of the initiation of the β-cell-specific 
AI process and characterizes the stage 1 of T1D. It reflects 
a critical increase in the risk of progression to diabetes, 
which is faster when the seroconversion with multiple 
autoantibodies occurs before the age of 3 years [14–16].
Children with T1D with early age at onset (EAO) pose 
a series of important challenges to health care profession-
als. The comprehension of the mechanisms dictating age 
at T1D onset may contribute to identify different pheno-
types of the disease and potentially to disclose new indi-
vidualized therapies.
In this study, we aimed to evaluate children with T1D 
before and after 5 years of age in terms of AI background, 
number and type of pancreatic autoantibodies, disease 
severity at onset and its correlation with white blood 




We performed a retrospective study including all children and ado-
lescents (up to 18 years of age) diagnosed with T1D in a central pedi-
atric hospital, in the period between January 2008 and March 2017. 
All cases of neonatal diabetes (onset ≤6  months) were excluded. 
The sample was divided into two groups according to age at disease 
onset: EAO ≤5 years and later age at onset (LAO) >5 years.
Informed consent was obtained from all individuals included in 
this study.
The research related to human use complied with all the relevant 
national regulations, institutional policies and was in accordance 
with the tenets of the Helsinki Declaration, and has been approved 
by the authors’ Institutional Review Board.
Data collection
Data was collected from records of each patient and included: demo-
graphic data, presence of other AI diseases until the end of the study 
(March 2018) and T1D presentation (diabetic ketoacidosis [DKA] or 
non-ketoacidosis). A peripheral blood sample was collected, within 
the first 3  days after diagnosis, for the following parameters: com-
plete white blood count (WBC), fasting C-peptide levels and pancre-
atic autoantibodies (glutamic acid decarboxylase 65 autoantibodies 
[GAD], tyrosine phosphatase-like insulinoma antigen 2 [IA2] and 
insulin autoantibodies [IAA]).
Screening for other AI diseases (celiac disease and thyroiditis) 
was performed at the time of diagnosis and annually.
One year after diagnosis, total daily insulin (TDI) (units per kg of 
body weight [U/kg]) and hemoglobin A1c (HbA1c, %) were evaluated.
Fasting C-peptide was determined by chemiluminescence 
(Immulite 2000 Siemens, Erlangen, Germany), pancreatic autoan-
tibodies were determined by radioimmunoassay (Medipan GmbH, 
Hamburg, Germany), and glycated hemoglobin (HbA1c) by chromato-
graphy (Variance 2-Biorad, Hercules, CA, USA).
DKA was defined as occasional blood glucose concentration 
>200 mg/dL (>11 mmol/L), venous pH <7.3 or bicarbonate <15 mmol/L 
and positive ketonemia or ketonuria. Severity of disease at onset was 
defined by the presence or absence of DKA at diagnosis.
Statistical analysis
Statistical analysis was performed using GraphPad Prism® ( GraphPad 
Software, La Jolla, CA, USA) and Microsoft office Excel 365® (Micro-
soft, Redmond, WA, USA). Data normally distributed is presented as 
mean ± standard deviation (SD) or as median and interquartile range 
(25th–75th percentile). Chi-square (χ2) tests were used for statistical 
comparisons for dichotomous and categorical variables. The Mann-
Whitney t-test was applied for unequally distributed variables. A 
p-value less than 0.05 was considered significant.
Results
Characteristics of the study population
The clinical characteristics of the 137 children who met 
the inclusion criteria are described in Table 1. Fifty-two 
children were included in the EAO group (mean age 
3.6 ± 1.5 years; 56% males) and 85 children were included 
in the LAO group (mean age 10.4 ± 2.9 years; 56% males).
The mean duration of diabetes was 4.1 ± 2 years in the 
EAO group and 3.8 ± 2 years in the LAO group.
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At the end of the first year of therapy, 73 children 
from the EAO group were treated with multiple daily 
injections (MDIs) and 15 started on continuous subcuta-
neous insulin infusion (CSII), whilst the LAO group were 
all on MDI.
EAO was more associated with other 
autoimmune diseases
In the EAO group, nine children presented another AI 
disease compared to five children in the LAO group 
(p = 0.032) (Table 1) until the end of the study. In the EAO 
group, five patients had AI thyroiditis and four had celiac 
disease. One child was diagnosed with celiac disease 
1 year before T1D and three had a diagnosis of another 
AI disease at the time of diabetes onset. In all the others, 
the associated AI disease was diagnosed 2–4 years after 
T1D. In the LAO group, two patients had celiac disease 
diagnosed at the time of diabetes onset and 1 year after, 
two had AI thyroiditis diagnosed 1 to 3 years after diabe-
tes onset, and one child had juvenile idiopathic arthritis 
diagnosed 6 years before T1D.
Innate immune response is significantly 
different in children ≤5 years and is related 
to residual β-cell function
The EAO group had higher initial absolute lympho-
cyte counts (median 4.5 × 103 cells/L [3.2–5.7] vs. 3.1 × 103 
cells/L [2.4–3.7], p < 0.0001) and lower neutrophil 
numbers (median 2.9 × 103 cells/L [2.4–3.7] vs. 3.5 × 103 
cells/L [2.4–4.9], p = 0.39) (Figure 1). Children in the EAO 
group also had lower fasting C-peptide levels at disease 
onset (median 0.2 ng/mL [0.1–0.3] vs. 0.3 ng/mL [0.2–0.5], 
p = 0.01).
Considering patients from both groups, we found 
an association between C-peptide levels ≤0.4 ng/mL 
and higher lymphocyte count at T1D onset (p = 0.0286) 
(Figure  2A). Moreover, there seems to be a  negative 
 correlation between fasting C-peptide levels and  absolute 
lymphocyte count (r = −0.215; p = 0.008) (Figure 2B).
Table 1: Clinical characteristics of the study population.
  ≤5 years  >5 years  p-Value
n, %   52 (38%)  85 (62%) 
Age, years (mean ± SD)   3.6 ± 1.5  10.4 ± 2.9 
Gender (male/female)   29/23  48/37 
Diabetes duration, years (mean ± SD)   4.1 ± 2  3.8 ± 2 
Insulin treatment (MDI/CSII)   37/15  85/0 
AI background (yes/no)   9/43  5/80  0.032
Diabetes presentation (DKA/non-DKA)   15/30  35/49  0.24
TDI, U/kg 1 year after diagnosis (median [25th–75th percentile])   0.72 (0.57–0.87)  0.6 (0.49–0.79)  0.008
AI, autoimmune; CSII, continuous subcutaneous insulin infusion; DKA, diabetic ketoacidosis; MDI, multiple daily injections; SD, standard 



























































































Figure 1: Lymphocytes and neutrophils at diagnosis in each of the 
two groups.
Percentages and absolute counts (cells/L) of lymphocytes 
and neutrophils from a peripheral blood sample collected at 
diabetes onset (within 3 days). Boxes show median (with 25% 
and 75% quartiles). Whiskers and outliers were plotted using the 
Tukey method. Ns, non-statistical. *p < 0.05 by the Mann-Whitney 
test.
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EAO had higher number of positive 
autoantibodies at presentation
At the time of diagnosis, the EAO group had more children 
with three positive autoantibodies than the LAO group 
(p = 0.008) (Figure 3). Overall, 10 children (7.3%) had all 
antibodies (Abs) negative. Regarding the type of Ab, the 
EAO group had more IAA (30 vs. 22, p = 0.0001) than LAO 
and less proportion of anti-GAD (35 vs. 61, p = 0.85) and anti-
IA2 (34 vs. 60, p = 0.77), although the difference in these last 
two autoantibodies was not statistically significant.
EAO and LAO had similar disease presentation
Evaluation of T1D severity at onset revealed that the 
proportion of patients presenting with ketoacidosis or 
non-ketoacidosis was similar in both groups (15/30 vs. 
35/49, p = 0.24) (Table 1). In eight patients, data for the 
presentation were not available.
One year after diagnosis, children with EAO 
require significantly higher insulin levels
One year after disease onset, HbA1c levels were similar 
in both groups (8.5 ± 0.9% vs. 8.4 ± 1.4%, p = 0.11). Not-
withstanding, EAO required higher doses of insulin when 
compared to the LAO group (median 0.72 U/kg [0.57–0.87] 
vs. 0.6 U/kg [0.49–0.79], p = 0.008) (Table 1). The TDI 
of children with CSII did not influence the differences 
between the two groups.
Discussion
The association between T1D and other AI diseases, such as 
Hashimoto’s thyroiditis and celiac disease, is well known 
and is likely related to a common genetic susceptibility 
[17, 18]. In fact, a high proportion of children and adoles-
cents with T1D have detectable islet autoantibodies, as well 
as other organ-specific autoantibodies [19, 20]. In these 
patients, the incidence of thyroiditis is approximately 
3–8% and the prevalence of celiac disease ranges from 
1 to 10% [20]. One of the main risk factors for the develop-
ment of another AI disease is the duration of T1D [20]. Our 
data show an association of EAO with a higher frequency 
of other AI diseases. Importantly, our results also show 
that 44% of EAO patients had another AI disease previ-
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Figure 2: Correlation between fasting C-peptide levels and absolute 
lymphocyte counts.
Lymphocyte count (cells/L) and C-peptide levels (ng/mL) from 
peripheral blood at diabetes onset (within 3 days). All patients were 
included from both groups. (A) A cut-off value for C-peptide levels 
≤0.4 ng/mL and >0.4 ng/mL was considered. Box shows median 
(with 25% and 75% quartiles). Whiskers and outliers were plotted 
using the Tukey method. *p < 0.05 by the Mann-Whitney test. (B) 
Absolute lymphocyte counts are shown in correlation to fasting 

































Number of children with 0, 1, 2 or 3 positive pancreatic 
autoantibodies according to age at disease onset. *p < 0.05 by 
the chi-square test. Autoantibodies performed: glutamic acid 
decarboxylase 65 (GAD), tyrosine phosphatase-like insulinoma 
antigen 2 (IA2) and insulin autoantibodies (IAA).
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duration is not the only factor underlying increased risk to 
develop additional AI disease. However, larger multicen-
tric studies are required to support these results, together 
with HLA typing.
T cell-mediated β-cell destruction is the predominant 
effector mechanism in T1D, but is not its primary cause. 
The mechanism behind the activation of the immune 
system and the cellular auto-attack is still not fully clear 
[21]. Our study shows that in EAO, the immune response 
seems significantly different.
EAO patients present at diagnosis lower neutrophil 
counts, higher lymphocyte numbers and less residual 
β-cell function, as reflected by lower C-peptide levels. 
Notably, we found an inverse correlation between lym-
phocyte number and fasting C-peptide levels. These 
results suggest that in the EAO group, exacerbated 
immune response has an important role in the anticipa-
tion of β-cell lesion.
To the best of our knowledge, few studies focused on 
this young group of patients until now. Szypwoska et al. 
studied the role of Tregs in the immune process in chil-
dren under 5  years of age. They reported that younger 
children had low levels of C-peptide and a low number 
of FoxP3 Tregs as well as immunosuppressive cytokines, 
such as interleukin-10 (IL-10) and transforming growth 
factor-β (TGF-β) [5]. It is known that abnormalities in Tregs 
may disrupt the balance between activation and suppres-
sion of the immune system leading to β-cell destruction. 
However, innate immune cells were not assessed in this 
study [22, 23].
Leete et al. found that the extension and progression 
of β-cell loss varies with age, and patients who develop 
T1D early in life (before the age of 7  years) tend to lose 
a superior extension of β-cells than those diagnosed in 
adolescence or later in life [1]. They suggest that insuli-
tis occurs in two distinct profiles according to the age at 
onset, with the main difference being the proportion of 
CD20+ β-cells present within the infiltrate, which leads to 
distinct aggressive phenotypes. Moreover, the proportion 
of insulin-containing islets is much lower in patients diag-
nosed at an early age which is consistent with our study 
and previous studies [1, 24].
Recently, Cabrera et  al. reinforced the hypothesis of 
subgroups with different immune response and disease 
progression. They used an index to calculate the ratio 
between inflammatory and regulatory genes and found 
that patients having lower innate inflammatory bias at the 
time of clinical onset were more likely to have slower rates 
of decline in residual insulin secretion. However, in this 
study, findings were independent from the age at clinical 
onset [25].
Despite the more evident immune imbalance in 
younger children, our data show that it was not associ-
ated with a more severe presentation, as both groups 
had similar number of DKA episodes. We believe that 
this similar presentation is related to the fact that symp-
toms are more visible at younger ages. Also, caregivers 
of younger children are more alert to symptoms and they 
probably seek medical advice sooner.
In our cohort, EAO patients had significantly more 
IAA. Other studies have similar results [26–29]. Kimpimäki 
et al. showed that IAAs are usually the first islet autoan-
tibodies to appear in the natural history of T1D and they 
are influential identifiers of disease progression in chil-
dren [26]. Higher IAA titer at younger ages of onset is 
consistent with the concept that these patients develop 
a more aggressive disease course as IAAs appear to be 
early markers of β-cell destruction [26–28]. In agreement, 
children with late-onset autoimmunity are less likely to 
present with IAA at seroconversion [29].
Individuals with early-onset islet autoimmunity 
present more frequently with multiple autoantibodies 
at the first positive sample. This may be due to the pres-
ence of multiple autoantibodies at seroconversion or oth-
erwise be a consequence of a shorter progression period 
from single to multiple autoantibodies, such that the first 
sample is more likely to miss the short period of single 
autoantibody positivity [29].
This is consistent with our results, as we have a sub-
stantially higher number of patients with three positive 
autoantibodies in the EAO group at the time of diagnosis.
Knip et al. studied the role of humoral β-cell autoim-
munity in T1D and they stated that the first signs of β-cell-
specific autoimmunity may appear early during the first 
months of life [30]. Hence it is likely that T1D appearance 
in young children reflects a process that began during the 
first 2 years of life or even during pregnancy [14]. In agree-
ment, most of the children diagnosed with T1D before 
puberty seroconvert to autoantibody positivity before the 
age of 3 years [14, 30].
On the other hand, in our study, 10 children (7.3%) 
presented with no autoantibody positivity. This propor-
tion is similar to the frequency described in other studies 
ranging from 3.6 to 7.9% [30]. These patients should nev-
ertheless be tested for other islet autoantibodies, namely 
ZnT8, which are currently not performed in our center.
Regarding the follow-up 1 year after diagnosis, our 
results demonstrate that the EAO group requires signifi-
cantly higher doses of insulin. Abdul-Rasoul et  al. in a 
study with diabetic children younger than 12 years showed 
that children below 5 years had lower remission rates than 
the older group [31]. Another study also demonstrated 
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that in children under the age of 5 years, partial remission 
is unusual [32]. This reflects the more aggressive and rapid 
destruction of β-cells and thus less residual insulin at the 
time of diagnosis [31].
Despite these results, the metabolic control between 
the two groups was similar. This is probably related to more 
careful supervision by caregivers in younger children.
In conclusion, our data show an association of EAO 
with more AI diseases, lower initial insulin reservoir 
(although similar disease presentation) and higher insulin 
requirements 1 year after diagnosis to achieve similar 
metabolic control. In EAO children, immune imbalance 
is more evident and disease progression is more rapid. 
Decreased neutrophil blood counts at diagnosis suggest 
the involvement of the innate immune system in pancre-
atic β-cell lesion. Pancreas donor studies would help to 
better understand the immunological peripheral blood 
changes.
Our results reveal important differences in the 
“immune environment” of children with different ages 
at onset, which may reflect more aggressive triggers of 
disease or “age-related” immune-genetic susceptibility 
phenotypes.
We believe that EAO T1D represents a suitable disease 
model to understand distinct T1D phenotypes. Further 
studies in the field of immunogenetics and immune tol-
erance are required to improve patient stratification and 
find novel targets for therapeutic intervention.
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